Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol. - Janssen, J. C.; van Dijk, B.; de Joode, K.; Aarts, M. J. B.; van den Berkmortel, F. W. P. J.; Blank, C. U.; Boers-Sonderen, M. J.; van den Eertwegh, A. J. M.; de Groot, J. W. B.; Jalving, M.; de Jonge, M. J. A.; Joosse, A.; et al. (BMC Cancer, 2024)